MedTrace Logo

Training for Men Undergoing Androgen Deprivation Therapy.

NCT06449664 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-06-10

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the effects of a newly developed training concept on men with prostate cancer undergoing androgen deprivation therapy (ADT).

The main questions it aims to answer are:

* How feasible and safe is the new training concept?
* How efficient is the training concept to counteract side effects caused by ADT?

Researchers will compare the new training concept with usual care to evaluate how efficient the training concept is to counteract the ADT-related side effects.

Participants in the intervention group will perform the new training concept twice weekly for 12 weeks. Participants in the control group will only receive usual care. All participants will visit the laboratory at baseline and after 6 and 12 weeks to measure the primary and secondary outcomes.

Conditions

Interventions

BEHAVIORAL

ADT-train

A new training concept is tested on men with prostate cancer receiving androgen deprivation therapy

Sponsors & Collaborators

  • Norwegian School of Sport Sciences

    collaborator OTHER

  • Karolinska Institutet

    collaborator OTHER

  • Prostate Cancer Foundation

    collaborator OTHER

  • Sahlgrenska University Hospital

    collaborator OTHER

  • The Swedish School of Sport and Health Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2026-12-31
Completion
2028-12-20

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06449664 on ClinicalTrials.gov